Ionis Pharmaceuticals, Inc.
Moat Score — Ionis Pharmaceuticals, Inc.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Ionis holds product-specific patents across seven approved medicines with protection running into the mid-2030s and beyond (e.g., zilganersen to at least 2041), built on a proprietary, decades-refined antisense oligonucleotide and MsPA chemistry platform that few competitors can replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | In-house API manufacturing at Carlsbad provides some cost control over R&D-stage production, but commercial-scale manufacturing relies on contract manufacturers, so this does not translate into a durable structural cost advantage versus competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the sole or near-sole approved therapy in several rare-disease indications (e.g., TRYNGOLZA for FCS, WAINUA as the only self-administered ATTRv-PN treatment), Ionis has meaningful orphan-drug-style pricing power, tempered by payer negotiations and eventual competitive entry. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Ionis's RNA-targeted medicines exhibit no network effect; a patient's or physician's value from a given drug does not increase as more patients are treated. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physicians and patients stabilized on a working ASO therapy (e.g., SPINRAZA for SMA) are often reluctant to switch given the severity of the underlying rare diseases, but none of Ionis's drugs involve hard technical lock-in beyond standard treatment-continuity considerations. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Ionis's broad, diversified partner network (AstraZeneca, Biogen, GSK, Novartis, Roche, Otsuka) and seven-product commercial base give it platform-level scale advantages that smaller single-asset RNA biotechs lack, though large pharma partners ultimately control much of the downstream commercial scale. |